News & Updates

Three anticancer drug regimens deliver moderate survival benefits to patients with relapsed/refractory (R/R) transplant-ineligible diffuse large B-cell lymphoma (DLBCL), particularly between the last treatment course and death, according to a study.

A novel platform that can identify tumour-specific alternative splicing (AS)–derived neoantigens with high confidence level could potentially overcome key stumbling blocks in cancer neoantigen vaccine development, according to Ms Bui Que Tran Nguyen of the Medical Genetics Institute, Ho Chi Minh City, Vietnam, who presented her team’s findings at ESMO TAT Asia 2026.

In acute leukaemia patients being treated with gemtuzumab-ozogamicin (GO) or inotuzumab-ozogamicin (InO), use of ursodiol prophylaxis does not appear to reduce the incidences of hepatoxicity, sinusoidal obstruction syndrome (SOS) or veno-occlusive disease (VOD), or time to grade 3 aspartate aminotransferase (AST) transaminitis, a study has shown.

Women undergoing medically assisted reproductive treatment seem to be at heightened risk of hormone-related cancers, as suggested in a study.

New drug applications approved by US FDA as of 1-15 July 2026 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

A multi-omics study by researchers from Japan has found that blood type B (BTB) is associated with reduced immune checkpoint inhibitor (ICI) efficacy in first-line (1L) treatment of head and neck squamous cell carcinoma (HNSCC).